10,189 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,189 shares of the company’s stock, valued at approximately $805,000.

Several other institutional investors have also added to or reduced their stakes in MIRM. Vanguard Group Inc. increased its position in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after acquiring an additional 50,720 shares during the period. State Street Corp boosted its holdings in shares of Mirum Pharmaceuticals by 59.2% during the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares during the period. Geode Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 1,062,926 shares of the company’s stock worth $83,975,000 after purchasing an additional 52,904 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after purchasing an additional 672,118 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Mirum Pharmaceuticals by 60.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 724,317 shares of the company’s stock worth $57,214,000 after purchasing an additional 273,479 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on MIRM. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wolfe Research began coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price for the company. Morgan Stanley raised their price target on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $139.80.

Mirum Pharmaceuticals Stock Up 0.5%

MIRM stock opened at $101.55 on Wednesday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $47.89 and a fifty-two week high of $114.99. The business’s 50 day moving average price is $98.17 and its two-hundred day moving average price is $91.67. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The company has a market capitalization of $6.19 billion, a price-to-earnings ratio of -7.46 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. During the same quarter in the previous year, the business earned ($0.30) EPS. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $93.82, for a total transaction of $469,100.00. Following the completion of the transaction, the chief financial officer owned 44,788 shares of the company’s stock, valued at approximately $4,202,010.16. The trade was a 10.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 8.32% of the stock is currently owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.